The peroxisome proliferator-activated receptor alpha (PPARα) agonist, fenofibrate (FF), known for its efficacy in DKD, has been shown to prevent DKD development by mediating NRF2 pathway activation through FGF21 (63). This evidence concerns the gene NFE2L2 and diabetic kidney disease.